Detection of mutations from liquid biopsies - applications in cancer diagnostics

Speaker

Abstract

Cell-free DNA (cfDNA) is currently trending as a biomarker from liquid biopsy in several clinical applications, including oncology, organ and transplant medicine, and non-invasive prenatal testing (NIPT). Although considerably less invasive than tissue biopsy, due to the small amount of cfDNA found in circulation, there is a need to use efficient, highly sensitive extraction protocols coupled with robust and reliable technologies, such as next-generation sequencing (NGS) to detect these mutations.

Join our webinar hosted by Monika Seidel (PhD) to discuss the results of a study using Cytiva’s magnetic silica bead-based Sera-Xtracta™ Cell-Free DNA extraction kit* and targeted NGS for cancer biomarker detection in advanced non-small cell lung cancer (NSCLC) patient samples. The study demonstrates performance in a clinically relevant scenario where patient samples are analyzed for therapy stratification.

Learning objectives

  • Discuss the opportunities and challenges created with liquid biopsy samples
  • Review the impact of cell-free DNA extraction efficiency, yield and purity in downstream applications such as next-generation sequencing 
  • Demonstrate performance of Sera-Xtracta Cell-Free DNA Kit in a clinically relevant scenario where patient samples are analyzed for therapy stratification

Show Resources
You May Also Like
FEB 24, 2021 10:00 AM PST
C.E. CREDITS
FEB 24, 2021 10:00 AM PST
DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
SEP 14, 2021 7:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
MAR 30, 2021 8:00 AM PDT
MAR 30, 2021 8:00 AM PDT
DATE: March 30, 2021 TIME: 08:00am PST In this talk, we will discuss the value of moving towards modular and automated, closed-system technologies designed to enable scalable and cost-effect...
APR 21, 2021 10:00 AM PDT
C.E. CREDITS
APR 21, 2021 10:00 AM PDT
Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
APR 07, 2021 9:00 AM PDT
C.E. CREDITS
APR 07, 2021 9:00 AM PDT
One challenge pharmaceutical companies face, is moving promising biotherapeutic products into the clinic as fast as safely possible. Devoting the correct amount of time and resources to earl...
C.E. CREDITS
Parkinson’s disease (PD) is the second most common neurodegenerative disorder with multiple motor and non-motor symptoms. PD is characterized by the presence on proteinaceous neuronal...
Loading Comments...
Show Resources